MSUD results from an inherited defect in oxidative decarboxylation of branched chainfi-keto acids (BCKA). Kinetic data for the BCKA decarboxylation were obtained with cultured fibroblasts of normal individuals and 9 MSUD patients with diffptjent ~linical~gictures. The liberation of C02 from (1-CIBCKA was determined by a microenzyme assay for substrate conc. ranging over three orders of magnitude. Of twb kinetically distinct decarboxylase components for each BCKA present in normal controls the one with higher substrate affinity was affected in all cases of MSUD investigated: for a-ketoisocaproate (KIc) the normally hyperffolic substrate curve was changed to sigmoid shape, foru-ketoisovalerate (KIVA) and k-keto-13-methylvalerate (MEVA) this componentwas not detectable at all. In one patient's cell strain, additionally, the componentwith lower substrate affinity was altered. The activity of phe-hydroxylase was determined in liver needle biopsy material from patients with elevated phe levels. The reaction mixture for the enzyme assay was: phosphate buffer 150mM, phe O.lrnM, phe 14C 0.2pCi. dithiothreitol 2mM, biopterin 0.025mM. The extract was preincubated with lysolecithin (ImM) for IOmin, the reaction stopped by boiling. Phe and tyr were separated by TLC. 14-C-activity was determined by direct scanning and counted in a liqufd scintillation counter.
So far we have observed 4 types of enzyme activity: 1) Control liver samples of non-metab lic disorders ransformed 9 100pmoles/g protein/60min4from phe to tyr. 2) Socalled hyperphe-aemia (phe levels around 10 mg%) had 10-2096 normal activity. 3) A third group had 1-696.
2 pairs of siblings also showed this residual activity. One sib in each family had not been t eated (late discovered) and was mentall) retarded, the other developed normally under treatment. The urinary Try metabolites from the kynurenine pathway and from indolic metabolism were analyzed in ten untreated PKUs.The results suggested a devision of the patients into groups A (higher serum Phe,reduced oxydative Try metabolism) and B (lower serum Phe and excessive excretion of oxydative metabolites and of N-acetyl-Try).One patient of group A was put on four semi-synthetic dietary re imes (70% free synthetic L-amino acidsf with varying Phe content,On a low Phe diet the excretion pattern of the oxydative and indolic metabolites became similar to that in group B.No reciprocal relationship between serum Phe and 5-OHindoleacetic acid was found.Numerous unidentified Try metabolites,specific for each group and certain dietary phases,were detected.The new analytical methods applied make it necessary to reaprise the previously published quantitative data on tryptophan metabolism in PKU.
R.BAUMGARTNER* and C.BACHMANN*(Intr.by G.Stalder).University Children's Hospital, Basel, Switzerland. Methylmalonic acidemia (MMA):Enzymatic studies in 5 non-related patients.
MMA may be caused by at least three diffe--ent enzyme defects:l)Defect of methylmalonylCoA(MMCoA)mutase-apoenzyme;2)Defective metabolism or transport of the coenzyme of MMCoA mutase.5'-deoxyadenosylcobalamin(dA-B12),or of its precursor,vitamin Blg;3)Deficiency of MMCoA racemase.-We have studied methylmalonate metabolism in leucocytes and cultured skin fibroblasts of 5 p.with MMA(1 p.Blq-responsive, 4 p.
clinically non-responsive). Intact fibroblasts of all 5 p.f 'led to metabolize 2-methyl-14c-malonate(MM-ftC)to 14~02,whether or not vitamin B12 or dA-~i2( 10-~~)were added;whereas in intact leucocytes of the 3 p.so far investigated, 1 4~0~ formation from MM-14~ was always present and similar to controls. Disrupted fibroblasts were studied using a s ecific enzyme assay with propionyl-CoA and NaHleC03 as substrates.Methylr malonate metabolism was absent or severely impaired in all p. as revealed by methylmalonate accumulation and succinate formation.While addition of vitamin ~~~( l o -" t o ~o -~M ) had no effect in any of the p.,addition of dA-~~~(l0-7 to ~o -~M ) did not enhance succinate formation in 2 p.,but fully restored enzyme activity in 2 other p.These data suggest a defective metabolism rather than a defective transport mechanism of the BIZ-coenzyme in the latter 2 p.
